Indication
Atypical Hemolytic Uremic
1 clinical trial
1 product
Clinical trial
Prospective, Single-Arm, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Complement Inhibitor Treatment-Naïve Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in ChinaStatus: Recruiting, Estimated PCD: 2026-03-31
Product
Eculizumab